WCO-IOF: Rituximab for rheumatoid arthritis positively impacts BMD of femoral neck
The effect of rituximab therapy on bone mineral density with rheumatoid arthritis patients
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
92 patients diagnosed with rheumatoid arthritis (RA) were randomized to receive methotrexate with or without rituximab therapy to assess the impact of rituximab treatment on bone mineral density (BMD) at the femoral neck. BMD and T-scores significantly increased after 3 years in patients who received methotrexate and rituximab therapy, and maintained positive trends at the 4-year follow-up. No sig...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE